Literature DB >> 10391939

Receptor for advanced glycation end products (RAGE)-mediated neurite outgrowth and activation of NF-kappaB require the cytoplasmic domain of the receptor but different downstream signaling pathways.

H J Huttunen1, C Fages, H Rauvala.   

Abstract

Receptor for advanced glycation end products (RAGE) mediates neurite outgrowth in vitro on amphoterin-coated substrates. Ligation of RAGE by two other ligands, advanced glycation end products or amyloid beta-peptide, is suggested to play a role in cell injury mechanisms involving cellular oxidant stress and activation of the transcription factor NF-kappaB. However, the RAGE signaling pathways in neurite outgrowth and cell injury are largely unknown. Here we show that transfection of RAGE to neuroblastoma cells induces extension of filopodia and neurites on amphoterin-coated substrates. Furthermore, ligation of RAGE in transfected cells enhances NF-kappaB-dependent transcription. Both the RAGE-mediated neurite outgrowth and activation of NF-kappaB are blocked by deletion of the cytoplasmic domain of RAGE. Moreover, dominant negative Rac and Cdc42 but not dominant negative Ras inhibit the extension of neurites induced by RAGE-amphoterin interaction. In contrast, the activation of NF-kappaB is inhibited by dominant negative Ras but not Rac or Cdc42. These data suggest that distinct signaling pathways are used by RAGE to induce neurite outgrowth and regulate gene expression through NF-kappaB.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10391939     DOI: 10.1074/jbc.274.28.19919

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  185 in total

Review 1.  New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal.

Authors:  S Müller; P Scaffidi; B Degryse; T Bonaldi; L Ronfani; A Agresti; M Beltrame; M E Bianchi
Journal:  EMBO J       Date:  2001-08-15       Impact factor: 11.598

Review 2.  The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses.

Authors:  A M Schmidt; S D Yan; S F Yan; D M Stern
Journal:  J Clin Invest       Date:  2001-10       Impact factor: 14.808

3.  Advanced glycation end-products (AGEs) induce concerted changes in the osteoblastic expression of their receptor RAGE and in the activation of extracellular signal-regulated kinases (ERK).

Authors:  Ana M Cortizo; María G Lettieri; Daniel A Barrio; Natalia Mercer; Susana B Etcheverry; Antonio D McCarthy
Journal:  Mol Cell Biochem       Date:  2003-08       Impact factor: 3.396

4.  Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury.

Authors:  Hideto Yonekura; Yasuhiko Yamamoto; Shigeru Sakurai; Ralica G Petrova; Md Joynal Abedin; Hui Li; Kiyoshi Yasui; Masayoshi Takeuchi; Zenji Makita; Shin Takasawa; Hiroshi Okamoto; Takuo Watanabe; Hiroshi Yamamoto
Journal:  Biochem J       Date:  2003-03-15       Impact factor: 3.857

5.  Argpyrimidine, a methylglyoxal-derived advanced glycation end-product in familial amyloidotic polyneuropathy.

Authors:  Ricardo Gomes; Marta Sousa Silva; Alexandre Quintas; Carlos Cordeiro; António Freire; Paulino Pereira; Américo Martins; Estela Monteiro; Eduardo Barroso; Ana Ponces Freire
Journal:  Biochem J       Date:  2005-01-15       Impact factor: 3.857

6.  Homodimerization is essential for the receptor for advanced glycation end products (RAGE)-mediated signal transduction.

Authors:  Hongliang Zong; Angelina Madden; Micheal Ward; Mark H Mooney; Christopher T Elliott; Alan W Stitt
Journal:  J Biol Chem       Date:  2010-05-26       Impact factor: 5.157

7.  The effect of sRAGE-Fc fusion protein attenuates inflammation and decreases mortality in a murine cecal ligation and puncture model.

Authors:  Su Jin Jeong; Beom Jin Lim; Sungha Park; Donghoon Choi; Hye Won Kim; Nam Su Ku; Sang Hoon Han; Chang Oh Kim; Jun Yong Choi; Young Goo Song; June Myung Kim
Journal:  Inflamm Res       Date:  2012-07-10       Impact factor: 4.575

8.  Targeting of RAGE-ligand signaling impairs breast cancer cell invasion and metastasis.

Authors:  T Kwak; K Drews-Elger; A Ergonul; P C Miller; A Braley; G H Hwang; D Zhao; A Besser; Y Yamamoto; H Yamamoto; D El-Ashry; J M Slingerland; M E Lippman; B I Hudson
Journal:  Oncogene       Date:  2016-09-26       Impact factor: 9.867

9.  Proinflammatory Effects of Respiratory Syncytial Virus-Induced Epithelial HMGB1 on Human Innate Immune Cell Activation.

Authors:  Kempaiah Rayavara; Alexander Kurosky; Susan J Stafford; Nisha J Garg; Allan R Brasier; Roberto P Garofalo; Yashoda M Hosakote
Journal:  J Immunol       Date:  2018-10-01       Impact factor: 5.422

10.  In vitro anticancer effects of a RAGE inhibitor discovered using a structure-based drug design system.

Authors:  Ali Hafez Ali Mohammed El-Far; Seiichi Munesue; Ai Harashima; Akira Sato; Mika Shindo; Shingo Nakajima; Mana Inada; Mariko Tanaka; Akihiko Takeuchi; Hiroyuki Tsuchiya; Hiroshi Yamamoto; Hazem M E Shaheen; Yasser S El-Sayed; Shuhei Kawano; Sei-Ichi Tanuma; Yasuhiko Yamamoto
Journal:  Oncol Lett       Date:  2018-01-29       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.